TABLE 3.

Representative high throughputing screened strategies for CoV infections.

Name of drugs	Mechanism of action	In vitro	In vivo	Clinical trial	Approved	References
Apilimod	PIKfyve kinase inhibitor	SARS-CoV-2	N.A.	SARS-CoV-2 (NCT04446377)	N.A.	Riva et al., 2020
MDL-28170	The cysteine protease inhibitor	SARS-CoV-2	N.A.	N.A.	N.A.	Riva et al., 2020
ONO 5334	The cysteine protease inhibitor	SARS-CoV-2	N.A.	N.A.	N.A.	Riva et al., 2020
Imatinib	Protein-tyrosine kinase inhibitor, lipid signaling, synthesis and metabolism, blocks the interaction of ACE2-Spike	SARS-CoV-2	N.A.	N.A.	Chronic myeloid leukemia and malignant gastrointestinal stromal tumors	Han et al., 2021
Mycophenolic acid	Inhibitor of IMPDH and guanine monophosphate synthesis	MERS-CoV, HBV, HCV, arboviruses (JEV, WNV, YFV, dengue virus and CHIKV) SARS-CoV-2	MERS-CoV	N.A.	Prevention of rejection after organ transplantation	Han et al., 2021
Quinacrine Dihydrochloride	Inhibits NF-κB and activates p53 signaling, lipid signaling, synthesis and metabolism, blocks the interaction of ACE2-Spike	SARS-CoV-2	N.A.	N.A.	Anti-malarial	Han et al., 2021